# MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial

> **NCT02678923** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 126 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** MDCO-216
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02678923
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-03
- **Primary completion:** 2016-10-26
- **Final completion:** 2016-10-26
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2017-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678923, "MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02678923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*